Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2017

View Archived Issues

AstraZeneca reviews key product and pipeline highlights of second quarter 2017

Daiichi Sankyo reflects on accomplishments of first quarter of fiscal 2017

CerSci Therapeutics obtains grant to support development of CT-044

Sanofi updates key developments of second quarter 2017

LAIV H5N2 vaccine demonstrates safety and long-lasting memory immune responses in healthy subjects

P2-VP8-P[8] subunit rotavirus vaccine shows safety and immunogenicity in toddlers and infants

Velusetrag improves symptoms in patients with gastroparesis in phase IIb study

Reduced tachyphylaxis seen in vivo with novel D1 receptor agonists

MRC announces two new partnerships with industry to speed drug discovery

Qu Biologics reports positive results from phase II study of QBECO

Helsinn and MEI Pharma begin phase III testing of pracinostat

IL-36 receptor identified as therapeutic target for IBD

Dosing begins in phase I study of Bolder Biotechnology's BBT-015

U.S. researchers patent EAAT2 activators

Bristol-Myers Squibb presents ROCK2 inhibitors

Kymab provides update on phase I study of KY-1005

Boehringer Ingelheim discloses BTK and IL-6 production inhibitors

RSV inhibitors identified by Enanta Pharmaceuticals

BioMarin to open additional phase III studies based on phase I/II data of BMN-270

FDA's arthritis advisory committee does not recommend approval of sirukumab for the treatment of RA

X4 Pharmaceuticals and Yale to work on genetic model of WHIM syndrome

FDA grants approval to ibrutinib for adult patients with chronic GvHD

Aclaris Therapeutics submits IND to FDA for ATI-50002

Proteostasis Therapeutics gives update on cystic fibrosis projects

IGF2BP3 found to be a novel target in thyroid cancer

Molecular Templates' merger with Threshold Pharmaceuticals completed

Takeda Pharmaceutical enters partnership with Cardurion Pharmaceuticals

Positive phase IIa results for GBR-830 as treatment of patients with atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...